Anzeige
Mehr »
Login
Samstag, 08.08.2020 Börsentäglich über 12.000 News von 643 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG ISIN: FR0010259150 Ticker-Symbol: I7G 
Tradegate
07.08.20
14:05 Uhr
84,45 Euro
-0,80
-0,94 %
Branche
Pharma
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
84,5085,4507.08.
84,9585,3007.08.

Aktuelle News zur IPSEN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIPSEN: Disclosure of Transactions in Own Shares Between 27/07/2020 and 31/07/2020144Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification code of the financial...
► Artikel lesen
IPSEN Aktie jetzt für 0€ handeln
30.07.Ipsen S.A. reports 1H results2
30.07.Ipsen Presents Its Half Year 2020 Results and Reinstates Guidance for Full Year 2020212Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2020. Resilient H1 financial...
► Artikel lesen
29.07.Gebrüder Weiss übernimmt Teile von Ipsen Logistics2
29.07.Gebrüder Weiss übernimmt Teile von Ipsen Logistics: Der Logistikdienstleister will mit dem ...2
28.07.IPSEN: Disclosure of Transactions in Own Shares Between 20/07/2020 and 24/07/2020185Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification code of the financial instrument Daily...
► Artikel lesen
21.07.Ipsen: Disclosure of Transactions in Own Shares Between 13/07/2020 And 17/07/2020168Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification code of thefinancial instrument Daily total...
► Artikel lesen
13.07.Ipsen +6.1% on share repurchase3
13.07.Ipsen: Disclosure of Transactions in Own Shares Between 06/07/2020 And 10/07/2020191Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification...
► Artikel lesen
10.07.Ipsen S.A.: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company292(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers Regulatory News: Ipsen S.A.: Market: Euronext Paris ISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 ...
► Artikel lesen
10.07.Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF238Regulatory News: Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF, as of June 30, 2020, the following resources were included to the dedicated liquidity account: 16...
► Artikel lesen
10.07.BRIEF-Ipsen Announces Updated Indication For Dysport For The Treatment Of Spasticity In Children1
07.07.Ipsen: Disclosure of Transactions in Own Shares Between 29/06/2020 And 03/07/2020187Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification...
► Artikel lesen
04.07.Neuer Chef für Ipsen: Ivo Sulovsky ist neuer General Manager der Ländergesellschaft der Ipsen-Gruppe ...2
02.07.Ipsen teams up for cabozantinib combo study in lung and prostate cancer-
02.07.BRIEF-Ipsen Joins Clinical Collaboration To Evaluate Lung And Prostate Cancer Treatments1
02.07.Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer267Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib Participation will provide Ipsen access to the respective study results to support...
► Artikel lesen
01.07.BRIEF-Ipsen Presents Phase I/II Clinical Data Evaluating Liposomal Irinotecan (Onivyde)1
01.07.Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer164Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan 5-fluorouracil/leucovorin (5-FU/LV) oxaliplatin (OX) (NALIRIFOX) to...
► Artikel lesen
30.06.Ipsen: Disclosure of Transactions in Own Shares Between 22/06/2020 And 26/06/2020185Regulatory News: Aggregated presentation by day and market Issuer name Issuer identification code Transaction date Identification code of the financial...
► Artikel lesen
Seite:  Weiter >>
106 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1